The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
2
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
3
FDA Grants Fast Track Status to SBE303 in Urothelial Cancer
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5